绝经后女性骨质疏松治疗降低骨折风险与安全性的系统评价、网状Meta分析及Meta回归分析:与安慰剂或阳性对照比较的随机临床试验
该系统评价、网状Meta分析和Meta回归分析纳入69项随机临床试验(超过8万例患者),比较双膦酸盐、地舒单抗、选择性雌激素受体调节剂、甲状旁腺激素受体激动剂和罗莫佐单抗对绝经后女性骨折风险的影响。结果显示双膦酸盐、甲状旁腺激素受体激动剂和罗莫佐单抗较安慰剂降低临床骨折风险;骨合成代谢治疗在预防临床和椎体骨折方面优于双膦酸盐,且不受基线风险指标影响。未观察到伤害结局,证据确定性为中至低。
要点
- 双膦酸盐、甲状旁腺激素受体激动剂和罗莫佐单抗较安慰剂降低临床骨折风险。
- 骨合成代谢治疗在预防临床和椎体骨折方面优于双膦酸盐,不受基线风险指标影响。
- 所有治疗均较安慰剂降低椎体骨折风险;未观察到伤害结局。
核心结论
- 证据表明多种骨质疏松治疗对绝经后女性的临床骨折和椎体骨折有益。
- 骨合成代谢治疗在预防临床和椎体骨折方面比双膦酸盐更有效,且不受基线风险指标影响。
- 因此该分析未提供临床证据支持将合成代谢治疗限制用于骨折风险极高的患者。
研究设计与样本
- 系统评价、网状Meta分析和Meta回归分析,纳入1996年1月1日至2021年11月24日发表的随机对照试验,比较双膦酸盐、地舒单抗、选择性雌激素受体调节剂、甲状旁腺激素受体激动剂和罗莫佐单抗与安慰剂或阳性对照。
- 纳入非亚洲绝经后女性,年龄不限,干预从骨质量 broad 角度考察;主要结局为临床骨折,次要结局包括椎体、非椎体、髋部、主要骨质疏松性骨折、全因死亡、不良事件和严重心血管不良事件。
- 结果基于69项试验(超过8万例患者)。
主要发现
- 与安慰剂相比,双膦酸盐、甲状旁腺激素受体激动剂和罗莫佐单抗对临床骨折有保护作用。
- 与甲状旁腺激素受体激动剂相比,双膦酸盐降低临床骨折的效果较差(比值比1.49,95%置信区间1.12至2.00)。
- 与甲状旁腺激素受体激动剂和罗莫佐单抗相比,地舒单抗降低临床骨折的效果较差(地舒单抗 vs 甲状旁腺激素受体激动剂:比值比1.85,95%置信区间1.18至2.92;地舒单抗 vs 罗莫佐单抗:比值比1.56,95%置信区间1.02至2.39)。
- 所有治疗与安慰剂相比均对椎体骨折有影响;在阳性治疗比较中,地舒单抗、甲状旁腺激素受体激动剂和罗莫佐单抗在预防椎体骨折方面比口服双膦酸盐更有效。
- 除抗骨吸收治疗外,所有治疗的效果不受基线风险指标影响;抗骨吸收治疗随着平均年龄增加,与安慰剂相比临床骨折的降低幅度更大(研究数=17;β=0.98,95%置信区间0.96至0.99)。
关键数值与推荐
- 与甲状旁腺激素受体激动剂相比,双膦酸盐降低临床骨折的比值比为1.49(95%置信区间1.12至2.00)。
- 与甲状旁腺激素受体激动剂相比,地舒单抗降低临床骨折的比值比为1.85(95%置信区间1.18至2.92);与罗莫佐单抗相比,地舒单抗的比值比为1.56(95%置信区间1.02至2.39)。
- 抗骨吸收治疗随平均年龄增加的临床骨折降低效应:β=0.98(95%置信区间0.96至0.99;研究数=17)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 所有个体结局的效应估计确定性为中至低,主要因报告局限性,名义上表明存在严重偏倚风险和 imprecision。
- 未观察到伤害结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors. DESIGN: Systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. DATA SOURCES: Medline, Embase, and Cochrane Library to identify randomised controlled trials published between 1 January 1996 and 24 November 2021 that examined the effect of bisphosphonates, denosumab, selective oestrogen receptor modulators, parathyroid hormone receptor agonists, and romosozumab compared with placebo or active comparator. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials that included non-Asian postmenopausal women with no restriction on age, when interventions looked at bone quality in a broad perspective. The primary outcome was clinical fractures. Secondary outcomes were vertebral, non-vertebral, hip, and major osteoporotic fractures, all cause mortality, adverse events, and serious cardiovascular adverse events. RESULTS: The results were based on 69 trials (>80 000 patients). For clinical fractures, synthesis of the results showed a protective effect of bisphosphonates, parathyroid hormone receptor agonists, and romosozumab compared with placebo. Compared with parathyroid hormone receptor agonists, bisphosphonates were less effective in reducing clinical fractures (odds ratio 1.49, 95% confidence interval 1.12 to 2.00). Compared with parathyroid hormone receptor agonists and romosozumab, denosumab was less effective in reducing clinical fractures (odds ratio 1.85, 1.18 to 2.92 for denosumab v parathyroid hormone receptor agonists and 1.56, 1.02 to 2.39 for denosumab v romosozumab). An effect of all treatments on vertebral fractures compared with placebo was found. In the active treatment comparisons, denosumab, parathyroid hormone receptor agonists, and romosozumab were more effective than oral bisphosphonates in preventing vertebral fractures. The effect of all treatments was unaffected by baseline risk indicators, except for antiresorptive treatments that showed a greater reduction of clinical fractures compared with placebo with increasing mean age (number of studies=17; β=0.98, 95% confidence interval 0.96 to 0.99). No harm outcomes were seen. The certainty in the effect estimates was moderate to low for all individual outcomes, mainly because of limitations in reporting, nominally indicating a serious risk of bias and imprecision. CONCLUSIONS: The evidence indicated a benefit of a range of treatments for osteoporosis in postmenopausal women for clinical and vertebral fractures. Bone anabolic treatments were more effective than bisphosphonates in the prevention of clinical and vertebral fractures, irrespective of baseline risk indicators. Hence this analysis provided no clinical evidence for restricting the use of anabolic treatment to patients with a very high risk of fractures. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42019128391.
引用
- Händel MN, Cardoso I, von Bülow C, et al. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ. 2023. PMID: 37130601. doi:10.1136/bmj-2021-068033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。